Cart
sales@molnova.com
YRGDS Fibronectin Fragment
CAS No. 134282-68-1
YRGDS Fibronectin Fragment ( )
Catalog No. M30229 CAS No. 134282-68-1
This is a fibronectin fragment, an adhesion peptide that displays strong binding affinity to thrombin-stimulated platelets. It is RGD consisting of sequence.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
Biological Information
-
Product NameYRGDS Fibronectin Fragment
-
NoteResearch use only, not for human use.
-
Brief DescriptionThis is a fibronectin fragment, an adhesion peptide that displays strong binding affinity to thrombin-stimulated platelets. It is RGD consisting of sequence.
-
DescriptionThis is a fibronectin fragment, an adhesion peptide that displays strong binding affinity to thrombin-stimulated platelets. It is RGD consisting of sequence.
-
Synonyms
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number134282-68-1
-
Formula Weight596.6
-
Molecular FormulaC24H36N8O10
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
Doherty DE, et al. Fibronectin fragments containing the RGDS cell-binding domain mediate monocyte migration into the rabbit lung. A potential mechanism for C5 fragment-induced monocyte lung accumulation. J Clin Invest. 1990 Oct;86(4):1065-75.
molnova catalog
related products
-
1-Kestose
1-Kestose shows significant anti-hydroxyl radical potential. 1-Kestose can promote intestinal Lactobacillus number and influence the microorganisms as well as the intestinal and systemic immune responses.
-
Skimmianin
Skimmianin is a spasmolytic agent. Skimmianin shows pharmacol. props. similar to 2-(Methylamino)-1-phenyl-1-propanol BCJ45-G.
-
Vazegepant HCl
Vazegepant is the first intranasal gepant for the acute treatment of migraine and has announced a positive phase II/III study.
